Lyra Therapeutics Is A Clinical Stage Biotechnology Company Based In Watertownmassachusettsfounded In 2005 And Renamed In 2018The Company Focuses On Developing Localizedlong Acting Therapies For Chronic Rhinosinusitiscrs A Condition Affecting Around 14 Million People In The U Sunder The Leadership Of Ceo Maria Palasislyra Has Approximately 30 Employees And Is Publicly Traded On Nasdaq Under The Ticker Lyra The Company Utilizes A Proprietary Drug Delivery Platform That Combines Bioabsorbable Materials With Anti Inflammatory Drugs To Create Sinonasal Implantsthese Implants Are Designed For Sustained Therapyallowing For Single Administration Treatments That Can Last Up To Six Monthslyra S Lead Productlyr 210Is Currently In Phase Iii Clinical Trials And Targets Crs Patients Without Prior Sinus Surgeryanother Productlyr 220Is In Development For Patients With A History Of Sinus Surgery Or Severe Anatomylyra Aims To Provide Long Lasting Symptom Relief For Patients Who Have Not Found Success With Traditional Treatments
